Precision BioSciences, Inc. (DTIL): Price and Financial Metrics

Precision BioSciences, Inc. (DTIL): $12.74

0.26 (-2.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add DTIL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#49 of 360

in industry

DTIL Price/Volume Stats

Current price $12.74 52-week high $27.00
Prev. close $13.00 52-week low $8.25
Day low $12.40 Volume 18,600
Day high $13.21 Avg. volume 108,590
50-day MA $12.06 Dividend yield N/A
200-day MA $11.97 Market Cap 88.24M

DTIL Stock Price Chart Interactive Chart >


Precision BioSciences, Inc. (DTIL) Company Bio


Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.


DTIL Latest News Stream


Event/Time News Detail
Loading, please wait...

DTIL Latest Social Stream


Loading social stream, please wait...

View Full DTIL Social Stream

Latest DTIL News From Around the Web

Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

DURHAM, N.C., December 13, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has received approval from the Australian Therapeutic Goods Administration for the initiation of a first-in-human Phase 1/2 trial evaluating ECUR-506, incorporating an ARCUS nuc

Yahoo | December 13, 2023

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

DURHAM, N.C., December 04, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled "Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease." This

Yahoo | December 4, 2023

Precision BioSciences to Present at Hep-DART 2023

DURHAM, N.C., November 30, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.

Yahoo | November 30, 2023

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employmen

Yahoo | November 28, 2023

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ...

Yahoo | November 14, 2023

Read More 'DTIL' Stories Here

DTIL Price Returns

1-mo 35.82%
3-mo -20.38%
6-mo 4.08%
1-year -42.54%
3-year -96.16%
5-year -96.96%
YTD 16.35%
2023 -69.33%
2022 -83.92%
2021 -11.27%
2020 -39.96%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!